Compare Axogen Inc (AXGN) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Tilray Brands Inc — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Tilray Brands Inc trades at $4.37 (market cap $540.74M). The key difference: Axogen Inc is far larger — about 3.8× Tilray Brands Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | TLRY | |
|---|---|---|
Market Cap | $2.06B | $540.74M |
Sector | Technology | Health |
52-Week High | $46.19 | $21.00 |
52-Week Low | $11.28 | $4.31 |
Enterprise Value | $1.98B | $637.89M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
TLRY trades at $4.46, up 0.9% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, though revenue grew to $821.31 million. Analyst consensus is cautious with 65% hold ratings, and recent news highlights expansion in medical cannabis and new product launches.
The outlook remains challenged by persistent losses and high debt levels, but low valuation ratios like P/S of 0.54 and P/B of 0.35 may attract value investors. Key risks include profitability struggles and regulatory uncertainty, while potential catalysts include international expansion and upcoming earnings on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
